

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

Mail Stop 4546

July 25, 2017

<u>Via E-mail</u> Mr. James Tripp Director and Acting Chief Executive Officer Rasna Therapeutics, Inc. 420 Lexington Avenue Suite 2525 New York, NY 10170

> Re: Rasna Therapeutics, Inc. Form 10-K for the Fiscal Year Ended June 30, 2016 Filed September 28, 2016 File No. 333-191083

Dear Mr. Tripp:

We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

/s/ Sharon M. Blume

Sharon M. Blume Accounting Branch Chief Office of Healthcare and Insurance